公开(公告)号：US20170331067A1

公开(公告)日：2017-11-16

申请号：US15522437

申请日：2015-07-21

Applicant: SAMSUNG SDI CO., LTD.

Inventor： Jae-Han PARK ,  Young-Kwon KIM ,  Jin-Hyun LUI ,  Eun-Sun YU ,  Han-ILL LEE ,  Ho-Kuk JUNG

IPC: H01L51/50 ,  C07D498/12 ,  H01L27/14

CPC classification number: H01L51/5056 ,  C07D498/12 ,  C09K11/06 ,  H01L27/14 ,  H01L51/0061 ,  H01L51/0067 ,  H01L51/0072 ,  H01L51/5004 ,  H01L51/5064 ,  H01L51/5072 ,  H01L51/508

Abstract: The present invention relates to an organic optoelectronic device and a display apparatus comprising same, the organic optoelectronic device comprising: an anode and a cathode facing each other; a light-emitting layer located between the anode and cathode; a hole transport layer located between the anode and light-emitting layer; an auxiliary hole transport layer located between the hole transport layer and light-emitting layer; an electron transport layer located between the cathode and light-emitting layer; and an auxiliary electron transport layer between the electron transport layer and light-emitting layer, wherein the auxiliary electron transport layer comprises at least one type of a first compound expressed by a particular Chemical Formula, and the auxiliary hole transport layer comprises at least one type of a second compound expressed by a particular Chemical Formula.

公开(公告)号：US20150166569A1

公开(公告)日：2015-06-18

申请号：US14622446

申请日：2015-02-13

Applicant: Genentech, Inc.

Inventor： Steven Staben ,  Georgette Castanedo ,  Christian A.G.N. Montalbetti ,  Jianwen Feng

IPC: C07D498/04 ,  C07D513/04 ,  C07D519/00 ,  C07D487/04

CPC classification number: C07D498/04 ,  C07D487/04 ,  C07D498/00 ,  C07D498/12 ,  C07D513/04 ,  C07D519/00

Abstract: The invention relates to novel compounds of Formula I: wherein A1, A2, A3, A4, A5, A6, R2, R4, R5, R6, R7, R8 and subscripts m and n each has the meaning as described herein. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.

Abstract translation: 本发明涉及式I的新化合物：其中A1，A2，A3，A4，A5，A6，R2，R4，R5，R6，R7，R8和下标m和n各自具有本文所述的含义。 式I化合物及其药物组合物可用于治疗观察到NF-kB信号传导的不期望或过度活化的疾病和病症。

公开(公告)号：US07964610B2

公开(公告)日：2011-06-21

申请号：US12294462

申请日：2007-03-27

Applicant: John William Lewis ,  Christopher Bourne Chapleo

Inventor： John William Lewis ,  Christopher Bourne Chapleo

IPC: A61K31/4748 ,  C07D491/08

CPC classification number: C07D498/12

Abstract: Ester derivatives of the phenolic hydroxyl group of buprenorphine can be used in the treatment of opiate dependency and/or moderate to severe pain. The esters have an enhanced bioavailability, an enhanced duration of action, and a reduced abuse potential.

Abstract translation: 丁丙诺啡的酚羟基的酯衍生物可用于治疗阿片依赖性和/或中度至重度疼痛。 酯类具有增强的生物利用度，增强的作用持续时间和减少的滥用潜力。

公开(公告)号：US07195882B2

公开(公告)日：2007-03-27

申请号：US10453256

申请日：2003-06-03

Applicant: Richard T. Root ,  Mitali Ghoshal

Inventor： Richard T. Root ,  Mitali Ghoshal

IPC: C01N33/535 ,  C01N33/533 ,  C07K16/44 ,  C07K17/06 ,  C07D451/00

CPC classification number: G01N33/9486 ,  C07D498/12 ,  C07K16/44

Abstract: The present invention relates to monoclonal antibodies that specifically bind buprenorphine and/or at least one metabolic product thereof. The present invention further relates to buprenorphine metabolite conjugates for the production of monoclonal antibodies that specifically bind buprenorphine and/or at least one metabolic product thereof and hybridoma cells that produce the monoclonal antibodies. The invention also relates to immunoassay methods for determining buprenorphine and/or one or more buprenorphine metabolites in a sample using the novel antibodies and conjugates of the present invention.

Abstract translation: 本发明涉及特异性结合丁丙诺啡和/或其至少一种代谢产物的单克隆抗体。 本发明还涉及用于产生特异性结合丁丙诺啡和/或其至少一种代谢产物的单克隆抗体的丁丙诺啡代谢物缀合物和产生单克隆抗体的杂交瘤细胞。 本发明还涉及使用本发明的新抗体和缀合物测定样品中丁丙诺啡和/或一种或多种丁丙诺非代谢物的免疫测定方法。

公开(公告)号：US09034892B2

公开(公告)日：2015-05-19

申请号：US13929003

申请日：2013-06-27

Applicant: Salix Pharmaceuticals, Inc.

Inventor： Karen S. Gushurst ,  Donglai Yang ,  Petinka Vlahova ,  Jeffrey S. Stults

IPC: C07D498/22 ,  A61K31/395 ,  A61P31/04 ,  C07D498/12

CPC classification number: C07D498/22 ,  C07D498/12

Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.

Abstract translation: 本发明涉及利福昔明多晶型物，盐，水合物和无定形形式，用于药物制剂和使用它们的治疗方法。

公开(公告)号：US20140141081A1

公开(公告)日：2014-05-22

申请号：US13929003

申请日：2013-06-27

Applicant: Karen S. Gushurst ,  Donglai Yang ,  Petinka Vlahova ,  Jeffrey S. Stults

Inventor： Karen S. Gushurst ,  Donglai Yang ,  Petinka Vlahova ,  Jeffrey S. Stults

IPC: C07D498/22

CPC classification number: C07D498/22 ,  C07D498/12

Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.

Abstract translation: 本发明涉及利福昔明多晶型物，盐，水合物和无定形形式，用于药物制剂和使用它们的治疗方法。

公开(公告)号：US20100036122A1

公开(公告)日：2010-02-11

申请号：US12446905

申请日：2007-10-24

Applicant: Jung Hun Suh

Inventor： Jung Hun Suh

IPC: C07D251/12

CPC classification number: C07D307/78 ,  A61K47/545 ,  A61K47/547 ,  C07D209/04 ,  C07D235/04 ,  C07D251/12 ,  C07D255/02 ,  C07D257/00 ,  C07D257/04 ,  C07D257/10 ,  C07D263/54 ,  C07D273/00 ,  C07D277/62 ,  C07D285/00 ,  C07D333/52 ,  C07D471/12 ,  C07D471/22 ,  C07D498/12

Abstract: The present invention relates to a cleavage agent and a cleavage method selectively acting on soluble assembly of amyloidogenic peptide or protein.

Abstract translation: 本发明涉及切割剂和切割方法，其选择性地作用于淀粉样蛋白生成肽或蛋白质的可溶性组装。

公开(公告)号：US20090118506A1

公开(公告)日：2009-05-07

申请号：US12212596

申请日：2008-09-17

Applicant: IN JONG KIM ,  Tongzhu Liu ,  Yao-Ling Qiu ,  Guoqiang Wang ,  Jiang Long ,  Heejin Kim ,  Yanchun Wang ,  Ly Tam Phan ,  Yat Sun Or

Inventor： IN JONG KIM ,  Tongzhu Liu ,  Yao-Ling Qiu ,  Guoqiang Wang ,  Jiang Long ,  Heejin Kim ,  Yanchun Wang ,  Ly Tam Phan ,  Yat Sun Or

IPC: C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  C07D401/14

CPC classification number: C07H17/08 ,  C07D213/69 ,  C07D213/80 ,  C07D309/40 ,  C07D498/12

Abstract: The present invention discloses compounds of formula I, II or, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

Abstract translation: 本发明公开了式I，II或其药学上可接受的盐，酯或前药的化合物：其表现出抗菌性质。 本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。 本发明还包括制备本发明化合物的方法。

公开(公告)号：US6124278A

公开(公告)日：2000-09-26

申请号：US54916

申请日：1998-04-03

Applicant: Gary A. Rogers ,  Peter Johnstrom

Inventor： Gary A. Rogers ,  Peter Johnstrom

IPC: A61K31/5365 ,  A61K31/55 ,  A61P25/00 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P43/00 ,  C07D498/12 ,  C07D498/14 ,  C07D498/04

CPC classification number: C07D498/12 ,  C07D498/14

Abstract: Compounds based on the benzoxazine ring system that are remarkably more potent than corresponding benzoyl piperidines for enhancing synaptic responses mediated by AMPA receptors are disclosed, as are methods for the preparation thereof, and methods for their use for treatment of subjects suffering from impaired nervous or intellectual functioning due to deficiencies in the number of excitatory synapses or in the number of AMPA receptors. The invention compounds can also be used for the treatment of non-impaired subjects for enhancing performance in sensory-motor and cognitive tasks which depend on brain networks utilizing AMPA receptors and for improving memory encoding.

Abstract translation: 公开了基于苯并恶嗪环体系的化合物，其相当于相应的苯甲酰哌啶用于增强由AMPA受体介导的突触反应的效力，其制备方法及其用于治疗患有神经或智力受损的受试者的方法 由于兴奋性突触数量或AMPA受体数量的不足而起作用。 本发明化合物还可用于治疗非受损受试者，以提高依赖于使用AMPA受体的脑网络和改善记忆编码的感觉运动和认知任务中的表现。

公开(公告)号：US20160200738A1

公开(公告)日：2016-07-14

申请号：US14995791

申请日：2016-01-14

Applicant: Salix Pharmaceuticals, Ltd

Inventor： Karen S. Gushurst ,  Donglai Yang ,  Petinka Vlahova ,  Jeffrey S. Stults

IPC: C07D498/22

CPC classification number: C07D498/22 ,  C07D498/12

Abstract: The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.

Abstract translation: 本发明涉及利福昔明多晶型物，其用于药物制剂和使用它们的治疗方法。